Katrien Berns
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
Journal: Molecular cancer therapeutics
Published: January 03, 2022
ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Journal: Biochimica et biophysica acta. Reviews on cancer
Published: May 25, 2018
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Journal: Oncogene
Published: November 27, 2017
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 27, 2017
Awakening of "Schlafen11" to Tackle Chemotherapy Resistance in SCLC.
Journal: Cancer cell
Published: February 16, 2017
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 18, 2015
Understanding resistance to targeted cancer drugs through loss of function genetic screens.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: November 13, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026